BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

...ACE2 - Angiotensin-converting enzyme 2 BSG (EMMPRIN; CD147) - Basigin Ok blood group CPD - carboxypeptidase...
BioCentury | Sep 10, 2012
Clinical News

Voraxaze glucarpidase regulatory update

...last month for the Medicare inpatient prospective payment system for FY13. FDA approved the recombinant carboxypeptidase...
BioCentury | Aug 20, 2012
Regulation

(Part) A for effort

...glucarpidase's intravenous delivery and the clear unmet medical need it addresses. Voraxaze is a recombinant carboxypeptidase...
BioCentury | Aug 11, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) Carboxypeptidase...
BioCentury | Feb 24, 2011
Distillery Techniques

Technology: Markers

...This week in techniques Approach Summary Licensing status Publication and contact information Markers N-terminal truncated carboxypeptidase...
BioCentury | Oct 1, 2009
Distillery Therapeutics

Indication: Endocrine disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Carboxypeptidase E (CPE) A...
BioCentury | Sep 10, 2007
Company News

Eden Biodesign, Cancer Research UK deal

...therapy to treat intra-abdominal cancer in combination with the prodrug CB1954; and Ad.CPG2, which expresses carboxypeptidase...
BioCentury | Apr 30, 2007
Clinical News

AZD9684: Development discontinued

...testing. AstraZeneca plc (LSE:AZN; AZN), London, U.K. Product: AZD9684 Business: Cardiovascular Molecular target: NA Description: Carboxypeptidase...
BioCentury | Nov 6, 2006
Company News

MediciNova, Meiji Seika Kaisha deal

...IIb/IIIa ( GPIIb/IIIa ) and integrin alpha(5)beta(1) receptors. MN-462 is a selective inhibitor of plasma carboxypeptidase...
BioCentury | Nov 2, 2006
Company News

Meiji licenses compounds to MediciNova, Cerexa

...IIb/IIIa ( GPIIb/IIIa ) and integrin alpha(5)beta(1) receptors. MN-462 is a selective inhibitor of plasma carboxypeptidase...
Items per page:
1 - 10 of 26